Also, the authors stated that the formula they used in this study, HTD1801 (berberine ursodeoxycholate or BUDCA), distinguishes itself from these agents in both structure and function and is different from other investigational agents used in NAFLD treatment, such as obeticholic acid, functioning as a farnesoid X receptor (FXR) agonist bile acid, aramchol, a liver-targeted SCD-1 inhibitor, and the thyroid hormone β agonist, resmetirom [68,149]. Here, NR1H4 is linked to metabolic dysfunction-associated steatotic liver disease.